Given that YS110 has a direct anti-proliferative effect on cancer cells, including malignant mesothelioma cells, these findings highlight the potential of rational therapy against CD26-positive cancers, not only through immunological ADCC and complementary activation effects, but also by direct inhibition of cancer cell growth. Here, DPP4 is linked to malignant mesothelioma.